Effect of duration of adjuvant chemotherapy with S-1 (6 versus 12 months) for resected pancreatic cancer: the multicenter clinical randomized phase II postoperative adjuvant chemotherapy S-1 (PACS-1) trial-Reference-Cited by-同舟云学术

Effect of duration of adjuvant chemotherapy with S-1 (6 versus 12 months) for resected pancreatic cancer: the multicenter clinical randomized phase II postoperative adjuvant chemotherapy S-1 (PACS-1) trial

Published:2023-08-08 Issue:11 Volume:28 Page:1520-1529
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Kayashima Hiroto,Itoh Shinji^ORCID,Shimokawa Mototsugu,Hayashi Hiromitsu,Takamori Hiroshi,Fukuzawa Kengo,Ninomiya Mizuki,Araki Kenichiro,Yamashita Yo-ichi,Sugimachi Keishi,Uchiyama Hideaki,Morine Yuji,Utsunomiya Tohru,Uwagawa Tadashi,Maeda Takashi,Baba Hideo,Yoshizumi Tomoharu

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s10147-023-02399-7.pdf

Reference25 articles.

1. Kobayashi K, Einama T, Takihata Y et al (2022) Therapeutic efficacy of dose-reduced adjuvant chemotherapy with S-1 in patients with pancreatic cancer: a retrospective study. BMC Cancer 22:1028

2. Itoh S, Tsujita E, Fukuzawa K et al (2021) Prognostic significance of preoperative PNI and CA19-9 for pancreatic ductal adenocarcinoma: a multi-institutional retrospective study. Pancreatology 21:1356–1363

3. Sultana A, Smith CT, Cunningham D et al (2007) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. J Clin Oncol 25:2607–2615

4. Sperti C, Pasquali C, Piccoli A et al (1997) Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 21:195–200

5. Klinkenbijl JH, Jeekel J, Sahmoud T et al (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230:776–782